Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 2Q

Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 2Q

2Q Revenues: $968.2 million (+1%)

2Q Earnings: $83.5 million (+227%)

YTD Revenues: $2.0 billion (+9%)

YTD Earnings: $225.2 million (+18%)

Comments: Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex. Other global Pharma revenues were $149.6 million (-16%). YTD Specialty Injectables sales were $1.2 billion (+29%). Other Pharma revenues were $295.7 million (-15%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics